Clinical trial
Interleukin-12 Gene Therapy in Treating Patients With Skin Metastases
NCT00028652 · University of Wisconsin, Madison, Other · Terminated
Key facts
| NCT number | NCT00028652 |
|---|---|
| Title | Interleukin-12 Gene Therapy in Treating Patients With Skin Metastases |
| Official title | Treament of Spontaneous Tumor Metastases With IL-12 DNA (NSC #709933): A Phase IB Trial |
| Lead sponsor | University of Wisconsin, Madison, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Terminated |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Metastatic Cancer |
| Intervention type | Biological |
| Interventions | interleukin-12 gene |
| Start date | Jan 1, 2002 |
| First posted | Jan 27, 2003 |
| Last update posted | Dec 13, 2019 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: